Real-World Evidence of the Safety and Survival with CD19 CAR-T Cell Therapy for Relapsed/Refractory Solid Organ Transplant-Related PTLD

Scientists conducted a multicentre real-world retrospective analysis of the use of CD19 CAR-T therapy in relapsed/refractory solid organ transplantation-related post-transplant lymphoproliferative disorders (PTLD) to provide guidance on treatment safety, efficacy, and patient prognostication.